Orion Oyj (ORINY)

Market Cap	16.14B +74.2%
Revenue (ttm)	2.47B +33.7%
Net Income	748.01M +110.3%
EPS	2.62 +110.1%
Shares Out	n/a
PE Ratio	22.14
Forward PE	18.51
Dividend	1.02 (1.75%)
Ex-Dividend Date	Oct 20, 2026

Volume	494
Open	58.05
Previous Close	57.78
Day's Range	58.05 - 58.05
52-Week Range	33.63 - 58.15
Beta	0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,215
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORINY

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error